NOSOCOMIAL ENTEROBACTER INFECTIONS: MECHANISMS OF RESISTANCE, CLINICAL IMPACT, AND INFECTION CONTROL STRATEGIES

Enterobacter species, particularly Enterobacter cloacae complex and Enterobacter aerogenes (reclassified as Klebsiella aerogenes), represent significant opportunistic pathogens responsible for an increasing proportion of nosocomial infections worldwide. Their propensity to colonize immunocompromised individuals and patients in intensive care units (ICUs) presents a major clinical challenge. This review provides a comprehensive analysis of the core resistance mechanisms, clinical implications, and infection control strategies associated with nosocomial Enterobacter infections. Mechanistically, Enterobacter species possess a formidable array of intrinsic and acquired resistance determinants. Central to their drug-resistant phenotype is the inducible, chromosomally encoded AmpC β-lactamase. Exposure to β-lactam antibiotics frequently selects for derepressed mutants that constitutively overproduce AmpC, conferring resistance to third-generation cephalosporins and monobactams. Furthermore, the rapid dissemination of plasmid-mediated resistance genes—including extended-spectrum β-lactamases (ESBLs) and carbapenemases (such as KPC, NDM, VIM, and OXA-48-like variants)—has severely compromised carbapenem utility. Coupled with efflux pump overexpression, porin mutations, and aminoglycoside-modifying enzymes, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains have emerged rapidly. Clinically, Enterobacter infections manifest primarily as ventilator-associated pneumonia, central line-associated bloodstream infections, catheter-associated urinary tract infections, and surgical site infections. These infections are correlated with prolonged hospital stays, heightened healthcare costs, and elevated morbidity and mortality, particularly when inappropriate empirical antimicrobial therapy is administered. The narrow range of remaining effective therapeutic options—often restricted to newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, polymyxins, or tigecycline—underscores the critical nature of these pathogens.

• Castanheira, M., Simner, P. J., & Bradford, P. A. (2021). Extended-spectrum β-lactamases, AmpC, and carbapenemases among Enterobacterales: Review of definitions, epidemiology, and detection. Journal of Clinical Microbiology, 59(7): e02700-20. https://doi.org/10.1128/JCM.02700-20,  Cited by: 312
• Davin-Regli, A., Lavigne, J. P., & Pagès, J. M. (2019). Enterobacter spp.: Update on taxonomy, clinical aspects, and susceptibility to antibiotics. Clinical Microbiology Reviews, 32(4): e00002-19. https://doi.org/10.1128/CMR.00002-19, Cited by: 420
• Harris, P. N. A., Wei, J. Y., Shen, M. W., Tambyah, P. A., Paterson, D. L., & Ferguson, J. K. (2016). Carbapenems versus alternative β-lactams for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 71(2): 296–306. https://doi.org/10.1093/jac/dkv346, Cited by: 185
• Jacoby, G. A. (2009). AmpC β-lactamases. Clinical Microbiology Reviews, 22(1): 161–182. https://doi.org/10.1128/CMR.00036-08,  Cited by: 1850
• Mezzatesta, M. L., Gona, F., & Stefani, S. (2012). Enterobacter cloacae complex: Clinical impact and emerging antibiotic resistance. Future Microbiology, 7(7): 887–902. https://doi.org/10.2217/fmb.12.61,  Cited by: 803
• Potter, R. F., Lainhart, W., Twentyman, J., Wallace, M. A., Wang, B., Burnham, C. A., & Dantas, G. (2018). Population genomics of Enterobacter cloacae complex isolates recovered from a single hospital system over a 10-year period. mBio, 9(5): e01479-18. https://doi.org/10.1128/mBio.01479-18,  Cited by: 145
• Sanders, C. C., & Sanders, W. E. Jr. (1986). Type I β-lactamases of gram-negative bacteria: Interactions with β-lactam antibiotics. The Journal of Infectious Diseases, 154(5): 792–800. https://doi.org/10.1093/infdis/154.5.792,  Cited by: 620
• Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021). Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clinical Infectious Diseases, 74(12): 2089–2114. https://doi.org/10.1093/cid/ciab1013.  Cited by: 647
• Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022). Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 75(2): 187–212. https://doi.org/10.1093/cid/ciac268, Cited by: 661 citation the review
• Meini S, Tascini C, Cei O, Sozio E, Rossolini GM. AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection, 2019; 47(3): 363–375.
• Davido B, Bateman R, Dinh A, Lawrence C. Antimicrobial stewardship and the management of Enterobacter cloacae complex infections: Avoiding the third-generation cephalosporin trap. J Hosp Infect, 2020; 106(2): 312–320.
• Kollef MH, Torres A, Shorr AF, Martin-Loeches I, Micek ST. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in prevention and treatment. Crit Care, 2021; 25(1): 180.
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by ESICM). Clin Microbiol Infect, 2022; 28(4): 521–547. 
• Falconer SB, Lao UV, Moody J, et al. Characterization of AmpR-mediated regulation of chromosomal AmpC expression in Enterobacter cloacae. Antimicrob Agents Chemother, 2021; 65(5): e02210–20.
• Patiño-Navarrte R, Rosas-Magaña G, Castro-Jaimes S, et al. Genomic and phenotypic characterization of Enterobacter bugandensis isolates associated with severe neonatal sepsis. Emerg Microbes Infect, 2023; 12(1): 2189402.
• Bonomo RA. β-Lactamases: A real threat to ampicillin, amoxicillin, and cephalosporins. Cold Spring Harb Perspect Med., 2017; 7(3): a0252
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization, 2024.
• Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. Cefepime testing and clinical outcomes in infections caused by AmpC-producing Enterobacterales: A systematic review and meta-analysis. Antimicrob Agents Chemother, 2020; 64(11): e01230–20.
• Centers for Disease Control and Prevention. Core Infection Prevention and Control Practices for Safe Healthcare Delivery in All Settings. Atlanta, GA: US Department of Health and Human Services, CDC, 2022.
• Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Optimizing β-lactam pharmacodynamics in the era of multidrug resistance: Extended and continuous infusions. Clin Pharmacokinet, 2021; 60(8): 981–995.
• Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of Klebsiella aerogenes and Enterobacter cloacae complex isolates from SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis., 2020; 96(3): 114945.
• Falconer R, Sfeir MM, Bonomo RA. Synergistic combinations of aztreonam and ceftazidime-avibactam against NDM-producing Gram-negative pathogens: A mechanistic review. Lancet Infect Dis., 2024; 24(2): e115–e126.